Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung

Ching Chih Chang, Sun Sang Wang, Hsian Guey Hsieh, Wen Shin Lee, Chiao Lin Chuang, Han Chieh Lin, Fa Yauh Lee, Shou Dong Lee, Hui Chun Huang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


The hepatopulmonary syndrome (HPS) is characterized by hypoxia and increased intrapulmonary shunts in cirrhotic patients. Emerging evidence showed promising results of treating HPS by abolishment of intrapulmonary inflammation and angiogenesis. Rosuvastatin is a kind of 3-hydroxy-methyl-3-glutamyl coenzyme A reductase inhibitor. In addition to lipid-lowering effects, it has anti-inflammation and anti-angiogenesis properties. We postulated that rosuvastatin treatment can ameliorate HPS. Common bile duct ligation (CBDL) was applied in an experimental HPS animal model. CBDL rats received 2-week rosuvastatin (20 mg/kg/day) treatments from the fifteenth day after operation. The haemodynamic data, blood gas analysis, liver biochemistries, tumour necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) were examined after rosuvastatin treatment. The liver and lung tissues were dissected for histopathological studies and protein analyses. In the parallel groups, intrapulmonary shunts were determined. The haemodynamic and liver biochemistries were not changed after rosuvastatin treatment in CBDL rats, but the alveolar-arterial oxygen pressure gradient was significantly decreased, implying that HPS-induced hypoxia was reversed after rosuvastatin treatment. In addition, rosuvastatin treatment reduced intrapulmonary shunts and plasma levels of VEGF and TNF-a. Besides, the intrapulmonary protein expression of nuclear factor kappa B (NF-κB), VEGF receptor (VEGFR)-1,2 and Rho-associated A kinase were significantly down-regulated and the intrapulmonary angiogenesis was ameliorated. We concluded that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via TNF-α/NF-κB and VEGF/Rho-associated A kinase pathways down-regulation.

Original languageEnglish
Pages (from-to)449-460
Number of pages12
JournalClinical Science
Issue number6
StatePublished - 2015


  • Hepatopulmonary syndrome
  • Inflammatory angiogenesis
  • Liver cirrhosis
  • Rosuvastatin


Dive into the research topics of 'Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung'. Together they form a unique fingerprint.

Cite this